ENDRA Life Sciences Reports Q1 2026 Financial Results
ENDRA Life Sciences Inc. reported its financial results for the first quarter of 2026 and announced that its Board of Directors is evaluating strategic alternatives for the company’s future.
ANN ARBOR, Mich.–(BUSINESS WIRE)—- $NDRA #MASLD–ENDRA Life Sciences Inc. (NASDAQ: NDRA) (“ENDRA” or the “Company”), a pioneer in thermoacoustic biomarker imaging for early detection and monitoring of steatotic liver disease (SLD), today reported financial results for the quarter ended March 31, 2026, and provided a business update. Business Update Initiated Evaluation of Strategic Alternatives On March 25, 2026, the Company announced that its Board of Directors has initiated a process to evaluate strategic